Congenital Muscular Dystrophy Ascending Multiple Dose Cohort Study Analyzing Pharmacokinetics at Three Dose Levels In Children and Adolescents With Assessment of Safety and Tolerability of Omigapil (CALLISTO)

Trial Profile

Congenital Muscular Dystrophy Ascending Multiple Dose Cohort Study Analyzing Pharmacokinetics at Three Dose Levels In Children and Adolescents With Assessment of Safety and Tolerability of Omigapil (CALLISTO)

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Sep 2017

At a glance

  • Drugs Omigapil (Primary)
  • Indications Congenital disorders; Muscular dystrophies
  • Focus Pharmacokinetics
  • Acronyms CALLISTO
  • Sponsors Santhera Pharmaceuticals
  • Most Recent Events

    • 29 Aug 2017 Planned primary completion date changed from 1 Oct 2017 to 15 Dec 2017.
    • 29 Aug 2017 Planned primary completion date changed from 1 Oct 2017 to 15 Dec 2017.
    • 29 Aug 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top